From the publishers of JADPRO
CAR T-Cell Therapy
Resource Center
Menu
Resources
Videos
Videos
Fast Facts
Quizzes
News & Literature Highlights
Case Studies
Advertisement
Test your knowledge of prophylactic strategies in selected high-risk or outpatient CAR-T populations
Last Updated: Monday, March 9, 2026
Loading...
Advertisement
News & Literature Highlights
Immunology
Strategies of AI-driven CAR-T cell therapy towards solid tumours
British Journal of Clinical Pharmacology
Efficacy, safety and cost-effectiveness of CAR-T therapy
Journal of Medical Economics
Time to access matters: Patient gains from faster CAR T-cell reimbursement in Europe
Blood Advances
CD19 CAR T-cell outcomes in relapsed/refractory extramedullary B-ALL: a multi-site, retrospective cohort review
Journal of Medical Cases
Cyclophosphamide for the treatment of refractory immune effector cell-associated neurotoxicity syndrome following CD19-targeted CAR T-cell therapy
Transplantation and Cellular Therapy
Financial toxicity in a phase I/II trial of LV20.19 CAR-T cell for B-cell malignancies a longitudinal, qualitative study
Experimental Biology and Medicine
Chimeric antigen receptor natural killer cell therapy for solid tumors: Mechanisms, clinical progress, and strategies to overcome the tumor microenvironment
Frontiers in Immunology
Impact of inotuzumab ozogamicin as bridging therapy and tumor burden in CAR-T therapy for B-acute lymphoblastic leukemia
Blood
Time of day of CAR T-cell infusion and outcomes in large B-cell lymphoma
Mayo Clinic Proceedings. Innovations, Quality, & Outcomes
Operationalizing access for chimeric antigen receptor T cell therapies: A cross-functional perspective
Advertisement
Case Studies
Prophylactic Tocilizumab in Selected High-Risk or Outpatient CAR-T Populations
Hemophagocytic Lymphohistiocytosis Following CAR T-Cell Therapy in a Patient With Multiple Myeloma
Bloodless Medicine Management of a Patient Receiving CAR T-Cell Therapy
Fast Facts
Fast Facts #12: BCMA Targets
Advertisement
Quizzes
Test your knowledge of prophylactic strategies in selected high-risk or outpatient CAR-T populations
How much have you learned this year?
Test your knowledge of hemophagocytic lymphohistiocytosis following CAR T-cell therapy in a patient with multiple myeloma